QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery a...

 hc-wainwright--co-maintains-buy-on-iteos-therapeutics-raises-price-target-to-46

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ITeos Therapeutics (NASDAQ:ITOS) with a Buy and raises the ...

Core News & Articles
Market-Moving News for May 10th
05/10/2024 12:41:27

ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering ...

 iteos-therapeutics-q1-2024-gaap-eps-107-misses-102-estimate

ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of ...

 jp-morgan-maintains-overweight-on-iteos-therapeutics-lowers-price-target-to-27

JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from ...

 hc-wainwright--co-reiterates-buy-on-iteos-therapeutics-maintains-44-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Buy and maintains ...

 iteos-therapeutics-q4-eps-085-beats-103-estimate-cash-and-investment-position-of-6327m-is-expected-to-provide-cash-runway-through-2026

ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(...

 iteos-to-highlight-preclinical-data-on-first-in-class-eos-984-targeting-ent1-at-the-american-association-for-cancer-research-annual-meeting-2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

 iteos-announces-2024-strategic-priorities-and-anticipated-milestones-cash-balance-and-investment-balance-of-6449m-as-of-september-30-2023-expected-to-provide-runway-through-2026

- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab ...

 jp-morgan-maintains-overweight-on-iteos-therapeutics-lowers-price-target-to-29

JP Morgan analyst Daniel Wolle maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from...

 iteos-therapeutics-q3-eps-090-beats-120-estimate-cash-cash-equivalents-and-investments-position-was-6449m-expected-to-provide-runway-through-2026

ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...